Brain Metastasis
50
10
10
14
Key Insights
Highlights
Success Rate
61% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
18.0%
9 terminated out of 50 trials
60.9%
-25.7% vs benchmark
8%
4 trials in Phase 3/4
29%
4 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (50)
A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial
Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
18F-FLUC PET/MR in Patients With Brain Mets
QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors
OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy
Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
NK Cell Therapy for Malignant Solid Brain Tumors
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
Feasibility of a Cognitive Stepped Care Program for Adults With Brain Metastases
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Evaluation of Neoadjuvant Stereotactic Radiosurgery (SRS) and Multi-fraction SRS Alone for the Treatment of Large Brain Metastases
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases